Cerivastatin - A new synthetic 3-hydroxy-3-methylglutaryl (HMG) inhibitor:Effect of 0.2 mg dose in patients with primary hyperlipidemias

Aim. To elucidate efficacy, safety and tolerance of lipobay (cerivastatin), a new HMC-CoA-reductase inhibitor (0.2 mg/day) in patients with primary hy perlipidemia (PHL). Materials and methods. The trial enrolled 15 men aged 21-64 years with PHL of type 2a and 26. After 1 and 3 months of treatment all the patients under went a general clinical examination with measurements of blood lipids (tota l cholesterol, triglycerides, high density lipoprotein cholesterol - HDL-C) , apolipoproteins (apo A-1 and apo B). Results. After 3 months of treatment total cholesterol, LDL-C and apolipopr otein B decreased by 24.94 +/- 2.57%, 23.94 +/- 3.08%, 19.32 +/- 2.43% (p = 0.0001), respectively, while LDL-C levels were < 3.4 mmol/l in 4 patients. Triglycerides dropped by 17.84 +/- 6.41%, while HDL-C rose by 5.01 +/- 4.4 7%, but the changes were not significant. Lipobay in doses 0.2 mg/day was w ell tolerated One patient stopped taking the drug because of severe abdomin al pain. Conclusion. Lipobay is a novel, effective and well-tolerated drug for treat ment of patients with primary hyperlipidemia of type 2a and 2b.